ImmunoPrecise Antibodies Net Tangible Assets

ImmunoPrecise Antibodies's net tangible assets stands at $15M as of January 2026. That compares with $25M in the prior-year period — down 40.4% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

ImmunoPrecise Antibodies reported $15M in net tangible assets versus $25M a year earlier — a 40.4% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $25M in the prior-year period — down 40.4% year over year. Sustained growth in net tangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how ImmunoPrecise Antibodies's net tangible assets evolved across reporting periods, while the comparison chart places IPA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, net tangible assets is commonly used to spot outliers. ImmunoPrecise Antibodies's reading of $15M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.